- The European Medicines Agency is investing a possible link between mRNA vaccines and erythema multiforme or two kidney disorders by a few recipients of the shots.
- Europe's drug regulator has requested additional data from Pfizer Inc PFE, BioNTech SE BNTX, and Moderna Inc MRNA.
- "We take adverse events that are potentially associated with our COVID-19 vaccine, BNT162b2, very seriously," Pfizer said in a statement. "We closely monitor all such events and collect relevant information to share with global regulatory authorities."
- "Serious adverse events that are unrelated to the vaccine are unfortunately likely to occur at a similar rate as they would in the general population," the company representative said.
- Moderna did not immediately respond to a request for comment.
- The European regulator did not reveal how many people had developed the new possible side effects.
- Erythema multiforme causes round skin lesions, which may also affect mucous membranes in internal body cavities.
- Nephrotic syndrome causes the kidneys to leak too much protein into the urine. Glomerulonephritis causes inflammation of the tiny filters in the kidneys.
- The EMA is also looking into menstrual side effects with all available adenovirus and mRNA COViD-19 vaccines.
- Price Action: PFE shares closed up 2.03% at $47.24, MRNA stock is +1.58% at $391.42, BNTX stock +4.13% at $374.02 on Thursday.
- Related content: Benzinga's Full FDA Calendar.
- See also: How to Buy Moderna (NASDAQ: MRNA) Stock
- Photo by x3 from Pixabay
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in